At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
COCP Cocrystal Pharma, Inc.
Market Closed 05-17 16:00:00 EDT
1.95
-0.01
-0.76%
盘后1.95
+0.000.00%
16:45 EDT
High2.07
Low1.80
Vol8.00K
Open1.90
D1 Closing1.97
Amplitude13.89%
Mkt Cap19.84M
Tradable Cap13.84M
Total Shares10.17M
T/O15.75K
T/O Rate0.11%
Tradable Shares7.10M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
COCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344…
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.